As of 2026-10-06, the Relative Valuation of Alnylam Pharmaceuticals Inc (ALNY) is 105.00 USD. This relative valuation is based on P/E multiples. With the latest stock price at 219.89 USD, the upside of Alnylam Pharmaceuticals Inc based on Relative Valuation is -52.3%.
The range of the Relative Valuation is 96.16 - 140.77 USD.
| Range | Selected | |
| Trailing P/E multiples | 17.9x - 23.3x | 18.7x |
| Forward P/E multiples | 26.4x - 36.5x | 26.6x |
| Fair Price | 96.16 - 140.77 | 105.00 |
| Upside | -56.3% - -36.0% | -52.3% |
| Date | P/E |
| 2026-10-05 | 36.33 |
| 2026-10-02 | 36.31 |
| 2026-10-01 | 38.20 |
| 2026-09-30 | 40.77 |
| 2026-09-29 | 41.98 |
| 2026-09-28 | 42.20 |
| 2026-09-25 | 42.29 |
| 2026-09-24 | 41.24 |
| 2026-09-23 | 40.73 |
| 2026-09-22 | 41.58 |
| 2026-09-21 | 40.37 |
| 2026-09-18 | 39.58 |
| 2026-09-17 | 40.57 |
| 2026-09-16 | 39.55 |
| 2026-09-15 | 39.37 |
| 2026-09-14 | 41.31 |
| 2026-09-11 | 41.09 |
| 2026-09-10 | 40.90 |
| 2026-09-09 | 42.63 |
| 2026-09-08 | 42.98 |
| 2026-09-04 | 43.97 |
| 2026-09-03 | 43.71 |
| 2026-09-02 | 44.18 |
| 2026-09-01 | 40.67 |
| 2026-08-31 | 39.77 |
| 2026-08-28 | 39.18 |
| 2026-08-27 | 39.09 |
| 2026-08-26 | 39.49 |
| 2026-08-25 | 39.67 |
| 2026-08-24 | 39.00 |
| 2026-08-21 | 39.03 |
| 2026-08-20 | 37.89 |
| 2026-08-19 | 40.09 |
| 2026-08-18 | 37.77 |
| 2026-08-17 | 37.11 |
| 2026-08-14 | 37.78 |
| 2026-08-13 | 37.53 |
| 2026-08-12 | 37.00 |
| 2026-08-11 | 36.55 |
| 2026-08-10 | 35.85 |
| 2026-08-07 | 36.22 |
| 2026-08-06 | 35.71 |
| 2026-08-05 | 37.79 |
| 2026-08-04 | 36.19 |
| 2026-08-03 | 36.41 |
| 2026-07-31 | 33.96 |
| 2026-07-30 | 33.95 |
| 2026-07-29 | 47.36 |
| 2026-07-28 | 47.66 |
| 2026-07-27 | 46.00 |